Shift to high‐intensity, low‐volume perfusion cell culture enabling a continuous, integrated bioprocess
Year: 2018
Type: article
Source: Biotechnology Progress
DOI: 10.1002/btpr.2723
Institutions: Pfizer (United States), Akston Biosciences (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funders: Pfizer, Boehringer Ingelheim
OpenAlex ID: W2897121698
